Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
SYDNEY, March 31, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to Cantrixil for USD 1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil In March 2021, Vivesto licensed the exclusive global development and commercialization rights for Cantr ...